LPGO — Lipigon Pharmaceuticals AB Income Statement
0.000.00%
Last trade - 00:00- SEK86.95m
- SEK61.97m
- SEK20.57m
Annual income statement for Lipigon Pharmaceuticals AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 8.02 | 4.42 | 0 | 32.8 | 20.6 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 24.2 | 86.8 | 75.5 | 57.6 | 71.7 |
| Operating Profit | -16.1 | -82.4 | -75.5 | -24.7 | -51.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -32.3 | -165 | -151 | -49 | -50.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -64.6 | -329 | -302 | -98 | -50.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -258 | -1,317 | -1,207 | -392 | -50.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -517 | -2,634 | -2,414 | -784 | -50.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -29.4 | -185 | -104 | -9.38 | -0.261 |
| Dividends per Share |